Business Description
Crism Therapeutics Corp
ISIN : VGG042401007
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.86 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 11.2 | |||||
3-Year EPS without NRI Growth Rate | 13.3 | |||||
3-Year FCF Growth Rate | 6.1 | |||||
3-Year Book Growth Rate | -48.1 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 1.85 | |||||
9-Day RSI | 13.85 | |||||
14-Day RSI | 23.78 | |||||
6-1 Month Momentum % | -30.56 | |||||
12-1 Month Momentum % | -30.56 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.56 | |||||
Quick Ratio | 6.56 | |||||
Cash Ratio | 5.3 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | -3.29 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 6303.23 | |||||
Net Margin % | 24035.48 | |||||
FCF Margin % | 3600 | |||||
ROE % | -250.79 | |||||
ROA % | -181.01 | |||||
ROIC % | -564.2 | |||||
ROC (Joel Greenblatt) % | -2760 | |||||
ROCE % | -55.74 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.43 | |||||
Price-to-Tangible-Book | 1.5 | |||||
EV-to-EBIT | -0.65 | |||||
EV-to-EBITDA | -0.65 | |||||
EV-to-Revenue | -34.8 | |||||
EV-to-FCF | -1.11 | |||||
Price-to-Net-Current-Asset-Value | 1.5 | |||||
Price-to-Net-Cash | 1.8 | |||||
Earnings Yield (Greenblatt) % | -153.47 | |||||
FCF Yield % | -37.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Crism Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil £) | -0.031 | ||
EPS (TTM) (£) | -0.856 | ||
Beta | 1.56 | ||
Volatility % | 252.1 | ||
14-Day RSI | 23.78 | ||
14-Day ATR (£) | 0.008681 | ||
20-Day SMA (£) | 0.09575 | ||
12-1 Month Momentum % | -30.56 | ||
52-Week Range (£) | 0.05 - 0.309 | ||
Shares Outstanding (Mil) | 32.68 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Crism Therapeutics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Crism Therapeutics Corp Stock Events
Event | Date | Price(£) | ||
---|---|---|---|---|
No Event Data |
Crism Therapeutics Corp Frequently Asked Questions
What is Crism Therapeutics Corp(LSE:CRTX)'s stock price today?
When is next earnings date of Crism Therapeutics Corp(LSE:CRTX)?
Does Crism Therapeutics Corp(LSE:CRTX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |